1. A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN (BV) AND LENALIDOMIDE (LEN) IN RELAPSED AND REFRACTORY (R/R) CUTANEOUS (CTCL) AND PERIPHERAL (PTCL) T‐CELL LYMPHOMAS: PRELIMINARY RESULTS OF A PHASE II TRIAL. (12th June 2019) Authors: William, B.M.; Abbasi, A.; Huang, Y.; Larbi, R.; Giali, R.; Yang, L.; Brammer, J.; Grantier, C.; Hoffman, C.; Ayyappan, S.; Baiocchi, R.; Epperla, N.; Christian, B.; Alinari, L.; Maddocks, K.; Chung, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 471 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY. (12th June 2019) Authors: Witzig, T.E.; Maddocks, K.; de Vos, S.; Lyons, R.; Edenfield, W.; Sharman, J.; Vose, J.; Yimer, H.; Wei, H.; Chan, E.; Patel, P.; Di Simone, C.; Gandhi, M.; Vaughn, J.; Kolibaba, K.; Cheson, B.; Samaniego, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. L‐MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R‐R DLBCL) – A SINGLE‐ARM PHASE II STUDY. (June 2017) Authors: Salles, G.; González Barca, E.; Jurczak, W.; Liberati, A.M.; Duell, J.; Nagy, Z.; Papajík, T.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P.L.; Ambarkhane, S.; Weirather, J.; Maddocks, K. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR). (12th June 2019) Authors: Hill, B.T.; Switchenko, J.M.; Martin, P.; Churnetski, M.C.; Sawalha, Y.; Goyal, S.; Shanmugasundaram, K.; Calzada, O.; Kolla, B.; Bachanova, V.; Gerson, J.N.; Barta, S.K.; Maldonado, E.; Gordon, M.; Danilov, A.; Grover, N.S.; Mathews, S.; Burkart, M.; Karmali, R.; Ghosh, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY. (12th June 2019) Authors: Bond, D.A.; Switchenko, J.; Maddocks, K.; Churnetski, M.; Goyal, S.; Shanmugasundaram, K.; Calzada, O.; Kolla, B.; Bachanova, V.; Gerson, J.; Barta, S.; Hill, B.; Salwaha, Y.; Martin, P.; Maldonado, E.; Gordon, M.; Danilov, A.; Grover, N.; Mathews, S.; Burkart, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 408 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PHASE I DOSE‐ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH‐RISK NON‐HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS. (12th June 2019) Authors: Maakaron, J.; Zhao, Q.; Puto, M.; Von Derau, R.; Robinson, J.; Brammer, J.; Penza, S.; Baiocchi, R.; Christian, B.; Maddocks, K.; Saad, A.; Wall, S.; Benson, D.; Efebera, Y.; Rosko, A.; Ayyappan, S.; Grieselhuber, N.; Vasu, S.; Larkin, K.; Epperla, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND). (12th June 2019) Authors: Salles, G.; Duell, J.; González Barca, E.; Jurczak, W.; Liberati, A.M.; Nagy, Z.; Obr, A.; Gaidano, G.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P.L.; Dirnberger‐Hertweck, M.; Weirather, J.; Ambarkhane, S.; Maddocks, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 173 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL). (23rd June 2022) Authors: Carlo-Stella, C.; Ansell, S.; Zinzani, P. L; Radford, J.; Maddocks, K.; Pinto, A.; Collins, G. P.; Bachanova, V.; Bartlett, N.; Bence-Bruckler, I.; Hamadani, M.; Kline, J.; Mayer, J.; Savage, K. J.; Advani, R.; Caimi, P.; Casasnovas, R.-O.; Feldman, T.; Hess, B.; Bastos-Oreiro, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. SECOND CANCER INCIDENCE IN CLL PATIENTS RECEIVING BTK INHIBITORS. (12th June 2019) Authors: Bond, D.A.; Huang, Y.; Fisher, J.; Ruppert, A.; Owen, D.; Bertino, E.; Rogers, K.; Bhat, S.; Jaglowski, S.; Grever, M.; Byrd, J.; Maddocks, K.; Woyach, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 382 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗